Liu et al. [126] treated NSCLC cell lines with a combination of second-generation EGFR inhibitors—afatinib and vinorelbine, a semi-synthetic vinca alkaloid—in low doses and found a reduction in anti-apoptotic proteins. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.